NOVACYT IS F**KING PISSING ME OFF.

Grab a cold one and read on, because you're not alone, but there's some very good reasons why you're not hearing what you want from the CEO, yet.

Strap in.

#NCYT #ALNOV @PrimerdesignLtd

First of all the drama a few months back, let's recap for newer investors - Novacyt goes from £5 to £2.

Every RNS the share price drops!

Yes, Nova was a speculative stock. All fair value estimates and sales were speculative. No-one in hanging around. And it gets worse as...

The CEO decides they've got so much cash coming in due to Covid-19 that they can get rid of the Private Equity sharks they're in debt to.

Debt gets converted into shares, and shares get sold en masse. Cue panic and everyone runs for the hills.

The company tanks to around £2...

Now to Novacyt, this means very little. They've shaken off all debt, and answer to less controlling interests. In the timeline of an ambitious diagnostics company, this is a microcosm, a few months of turbulence. Meaningless.

To investors. It's catastrophe...

This left Novacyt in the curious position of being bizarrely undervalued by Market Cap at around £2. In the months to come, the share price would slowly ascend as confidence returned, tentatively. Investors averaged down and bought cheap shares all the way to £3...

This process took months and without any real word on sales figures, or how money was spent on R&D, the market still viewed NCYT with a weary eye. Too many New speculative stocks emerged, promising Billions in sales Globally. Why even bother with a beaten up PCR biotech...

Especially one that was quiet. The occasional relief came by way of RNS on new products, but lacking indicative sales forecasts that the market needed to excite it. It was your boring value stock. Undervalued, but so what, you can get 500% on some other wonder Biotech, maybe...

As we rolled into August, frustration that no sales updates came for July, and as September came, no sales updates for September!

Okay, RECAP over.

Here's why...

Novacyt's plan are larger than making some cash and roping you along for a quick test that may or many not be accurate enough to use as a diagnostic (NO fast test so far has 'diagnostic accuracy' even Abbott, industry giants.

Novacyt is working to build industrial scale testing

That ALL countries across the world can rely on for Public Health program screening and diagnosis. 100% tests for Flu/Covid/RSV. Testing programs which have an average speed of SECONDS per TEST when done in bulk in large labs - like the UK's new AZN/Cambridge/NCYT Super Labs

To achieve this scale and quality of testing requires complex work and massive R&D, at levels other biotechs trying to get a novelty fast test out cannot compete with.

While the past few months have been silent on investor's end, Nova has been developing groundbreaking tests...

Which will be used year round globally, by all labs and private groups. Even when retail tests, and the Govt's decide they no longer need interesting 'fast tests', labs around the world will be using WinterPlex daily, around the clock, for years. One test, to detect them all...

This test, to be used in existing machines globally, will screen populations en masse for Flu/Covid-19 and RSV. Statistical models of viruses will rely on this testing. Government policy will rely on it. Our health, and economies, will rely on it...

As Novacyt grew into a monster, growth amplified by the Covid-19 catalyst accelerating its development a decade ahead, so too did reporting requirements. NCYT no longer has any material need to tell you it made a few million this week on some contract.

Things have changed...

Novacyt's updates will now come when large audits of its complex multi subsidiary structure have been carried out, and products which have the ability to drive significant growth are released.

No more monthly sales. You will get massive beautifully produced updates at AGM's..

Half Yearly Updates, Annual Updates, and when something truly huge, like £200million+ single contracts are landed by a Govt. Then you'll see that hit the RNS promptly, after the Govt. announces it first.

So where is the UK Govt. Tender, there's be so much noise after all?

Novacyt has operated outside of the Tender process since December 2019 when it first spotted the need for Covid-19 tests. It worked with PHE, NHS Trusts and DHSC. And has continued to do so every step of the way.

There is no company doing this in any capacity even close to it..

All the bizarre contract wins for example DNAnudge and all the Big Win talk the Gov puts out about new fast tests is publicity and distraction.

What is really going on behind the scenes is the rebuilding of a UK National Diagnostic network. Industrial scale.

The UK will never be caught out again by another Covid-19 spike, or another virus. Because Novacyt, Deloitte, AstraZeneca and Cambridge University have build Super Labs, with robotic assistance to increase throughput.

NCYT CEO said they no longer release RNS's like before...

Because Novacyt has transformed.

When the updates really come, they will reveal scales of work that are not comparable to other biotechs trying to cash in on a crisis.

And they will reveal revenue to reflect the scale of their work. @PrimerdesignLtd this week also indicated..

That they will not be acting like other companies we're discussing. They have elevated beyond stringing investors along. This means no tactical weekly RNS's announcing something insignificant.

Novacyt is no longer a speculative stock...

It's been a value stock for 3 months. And now it's about to return to being a growth stock. That will be spectacular. You've probably forgotten what it feels like to see Novacyt do 20%+ days. 50%+ days.

NCYT AGM is in 3 weeks.

NCYT is now a 3 week Conviction Hold.

Strap in.